En vivo
Endpoints NewsMerck brings Welireg-Keytruda combo to treat kidney cancerClinical OMICsFrom Multi-Omics to Digital Twins: A Data-Driven Future for Precision MedicineClinical OMICsAge-Related Mutations in Brain Immune Cells Linked to Alzheimer’s InflammationClinical OMICsPaper Mills and the Fight Against Scientific FraudClinical OMICsNanowire Device Captures EVs for Targeted Cancer Liquid BiopsiesCellComplete biosynthesis of the anticancer cephalotaxinone and homoerythratineEndpoints NewsAmgen and the FDA want two different outcomes for Tavneos. What will patients do?Endpoints NewsEli Lilly invests in startup Abridge for clinical trial recruitmentBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 11, 2026Thermo FisherThermo Fisher Tests SpheriCal Calibration As Potential Edge In Mass Spectrometry - Yahoo FinanceLonza NewsAmMax Bio licenses antibody-drug conjugate technology for haematological cancers from Lonza - Manufacturing Chemist
Endpoints News 28 abr 2026

AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel

AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel

Original
Contenido no disponible. Consulta la fuente original.